Skip to main content

Recombinant Human/Mouse Wnt-5a Protein Best Seller

R&D Systems, part of Bio-Techne | Catalog # 645-WN

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
Carrier Free
645-WN-010/CF

Catalog #
Availability
Size / Price
Qty
With Carrier
645-WN-010

Key Product Details

Source

CHO

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived Wnt-5a protein
Gln38-Lys380

Purity

>80%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Asn44 & No results obtained: Gln38 predicted

Predicted Molecular Mass

38 kDa

SDS-PAGE

45 kDa, reducing conditions

Activity

Measured by its ability to inhibit Wnt-3a-induced alkaline phosphatase production by MC3T3-E1 mouse preosteoblast cells.
The ED50 for this effect is 0.1-0.5 µg/mL, in the presence of 5 ng/mL rmWnt-3a.
Optimal concentrations should be determined by each laboratory for each application.

Reviewed Applications

Read 8 reviews rated 5 using 645-WN in the following applications:

Scientific Data Images for Recombinant Human/Mouse Wnt-5a Protein

Graph showing dose-dependent bioactivity of mouse Wnt-5a protein

Bioactivity of Mouse Wnt-5a

Recombinant mouse Wnt-5a (645-WN) inhibits Wnt-3a-induced alkaline phosphatase production in the MC3T3-E1 mouse preosteoblast cell line. The ED50 for this effect is 0.1-0.5 µg/mL in the presence of 5 ng/mL recombinant mouse Wnt-3a (1324-WN).

Formulation, Preparation and Storage

Carrier Free
What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: 645-WN
Formulation Lyophilized from a 0.2 μm filtered solution in PBS, EDTA and CHAPS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Carrier Free: 645-WN/CF
Formulation Lyophilized from a 0.2 μm filtered solution in PBS, EDTA and CHAPS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Wnt-5a

Wnt-5a is a 44‑50 kDa member of the Wnt family of proteins (1‑6). Based on its activity towards C57Mg mammary epithelium, it is classified as a nontransforming Wnt. Human Wnt‑5a is synthesized as a 380 amino acid (aa) precursor that contains a 37 aa signal sequence, a 25 aa prosegment, and a 319 aa mature region (1, 2, 3). The mature region has 24 cysteine residues that form multiple intrachain disulfide bonds, plus four N‑linked glycosylation sites that are utilized for proper secretion (3, 5, 7). There is also a palmitate adduct at Cys104 that is essential for activity, and a potential palmitoleic acid modification at Ser244 that may also contribute to secretion (7‑9). One alternative start site is reported at Met16. Over aa 38‑380, human and mouse Wnt‑5a are identical in amino acid sequence (1, 10). Cells known to express Wnt‑5a include brainstem astrocytes (11), mammary epithelium (12), CD34+ primitive progenitor stem cells (13), chondrocytes (14), CD34- pericytes and vascular smooth muscle cells (15), plus mesenchymal cells at various sites (16, 17). There are multiple receptors for Wnt‑5a. These include Fzd-1, -2,
-3, -4, -5, and -7 (3, 18‑22), Ror2 (3), LRP6 (23), Ryk (24) and sFRP1 (25). All these molecules function within the context of a larger number of “co‑factors” that regulate signaling by the Wnts. Initially, it was suggested that there were three pathways for Wnt signaling; a beta-catenin-mediated canonical pathway, and two noncanonical pathways described as the Wnt/JNK (PCP) pathway and the Wnt/Ca++ pathway (26, 27). And it was assumed that various Wnts could be accommodated by these classifications. At present, it is now recognized that individual Wnts, through various combinations of receptor complex subunits, can have diverse effects, perhaps even within the same cell (3, 6, 27). Further complexity is introduced by the fact that Xenopus Wnt‑5a and Wnt‑11 are known to form bioactive heterodimers following Tyr sulfation (28). Thus, predicting the activity of Wnt‑5a, or any other Wnt, on any cell type will require substantial insight into the interaction between all the extracellular, cell surface and intracellular components of the Wnt signaling system.

References

  1. Clark, C.C. et al. (1993) Genomics 18:249.
  2. LeJeune, S. et al. (1995) Clin. Cancer Res. 1:215.
  3. Mikels, A.J. & R. Nusse (2006) PLoS Biol. 4:e115.
  4. Nishita, M. et al. (2010) Trends Cell Biol. 20:346.
  5. Mikels, A.J. & R. Nusse (2006) Oncogene 25:7461.
  6. van Amerongen, R. & R. Nusse (2009) Development 136:3205.
  7. Kurayoshi, M. et al. (2007) Biochem. J. 402:515.
  8. Takada, R. et al. (2006) Dev. Cell 11:791.
  9. Port, F. & K. Basler (2010) Traffic May 3. [Epub ahead of print].
  10. Gavin, B.J. et al. (1990) Genes Dev. 4:2319.
  11. Castelo-Branco, G. et al. (2006) Mol. Cell. Neurosci. 31:251.
  12. Jonsson, M. et al. (1998) Br. J. Cancer 78:430.
  13. van Den Berg, D.J. et al. (1998) Blood 92:3189.
  14. Kruger, C. & C. Kappen (2010) PLoS One 5:e8978.
  15. Lin, G. et al. (2008) Stem Cells Dev. 17:1053.
  16. Lickert, H. et al. (2001) Mech. Dev. 105:181.
  17. Danielson, K.G. et al. (1995) J. Biol. Chem. 270:31225.
  18. Gazit, A. et al. (1999) Oncogene 18:5959.
  19. Bazhin, A. V. et al. (2010) Cell. Mol. Life Sci. 67:817.
  20. Kawasaki, A. et al. (2007) Cell. Signal. 19:2498.
  21. Blumenthal, A. et al. (2006) Blood 108:965.
  22. Umbhauer, M. et al. (2000) EMBO J. 19:4944.
  23. Bryja, V. et al. (2009) Mol. Biol. Cell 20:924.
  24. Keeble, T.R. et al. (2006) J. Neurosci. 26:5840.
  25. Lin, K. et al. (1997) Proc. Natl. Acad. Sci. USA 94:11196.
  26. Rao, T.P. & M. Kuhl (2010) Circ. Res. 106:1798.
  27. McDonald, S.L. & A. Silver (2009) Br. J. Cancer 101:209.
  28. Cha, S-W. et al. (2009) Curr. Biol. 19:1573.

Long Name

Wingless-type MMTV Integration Site Family, Member 5a

Alternate Names

Wnt5a

Entrez Gene IDs

7474 (Human); 22418 (Mouse)

Gene Symbol

WNT5A

UniProt

Additional Wnt-5a Products

Product Documents for Recombinant Human/Mouse Wnt-5a Protein

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human/Mouse Wnt-5a Protein

For research use only

Loading...
Loading...
Loading...